RE-BVS – Piemonte Repository

Sfoglia per AUTORE
OCIO EM
Collezione AOU Città della Salute di Torino

Items : 7

30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis. in HemaSphere / Hemasphere. 2024 Nov 5;8(11):e70041. doi: 10.1002/hem3.70041. eCollection 2024 Nov.

2024
AOU Città della Salute di Torino

Ocio EM; Perrot A; Moreau P; Mateos MV; Bringhen S; Martínez-López J; Karlin L; Wang SY; Oprea C; Li Y; Kodas E; San-Miguel J;

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation. in Leukemia / Leukemia. 2023 Jul;37(7):1521-1529. doi: 10.1038/s41375-023-01936-7. Epub 2023 Jun 14.

2023
AOU Città della Salute di Torino

Ocio EM; Perrot A; Bories P; San-Miguel JF; Blau IW; Karlin L; Martinez-Lopez J; Wang SY; Bringhen S; Marcatti M; Mateos MV; Rodriguez-Otero P; Oliva S; Nogai A; Le Roux N; Dong L; Macé S; Gassiot M; Fitzmaurice T; Oprea C; Moreau P;

Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients. in HemaSphere / Hemasphere. 2023 Jan 31;7(2):e829. doi: 10.1097/HS9.0000000000000829. eCollection 2023 Feb.

2023
AOU Città della Salute di Torino

Ocio EM; Bringhen S; Martinez-Lopez J; San-Miguel J; Oliva S; Rodriguez-Otero P; Le Roux N; Dong Y; Doroumian S; Macé S; Mateos MV;

Melflufen for the treatment of multiple myeloma. in Expert review of clinical pharmacology / Expert Rev Clin Pharmacol. 2022 Apr;15(4):371-382. doi: 10.1080/17512433.2022.2075847. Epub 2022 Jun

2022
AOU Città della Salute di Torino

Ocio EM; Nadeem O; Schjesvold F; Gay F; Touzeau C; Dimopoulos MA; Richardson PG; Mateos MV;

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. in The Lancet. Oncology / Lancet Oncol. 2021 Mar;22(3):e105-e118. doi: 10.1016/S1470-2045(20)30756-7.

2021
AOU Città della Salute di Torino

Moreau P; Kumar SK; San Miguel J; Davies F; Zamagni E; Bahlis N; Ludwig H; Mikhael J; Terpos E; Schjesvold F; Martin T; Yong K; Durie BGM; Facon T; Jurczyszyn A; Sidana S; Raje N; van de Donk N; Lonial S; Cavo M; Kristinsson SY; Lentzsch S; Hajek R; Anderson KC; João C; Einsele H; Sonneveld P; Engelhardt M; Fonseca R; et alii...

Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. in Journal of clinical medicine / J Clin Med. 2020 Sep 27;9(10):3120. doi: 10.3390/jcm9103120.

2020
AOU Città della Salute di Torino

Mateos MV; Bladé J; Bringhen S; Ocio EM; Efebera Y; Pour L; Gay F; Sonneveld P; Gullbo J; Richardson PG;

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.

2019
AOU Città della Salute di Torino

Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;